Biotech Values

[DewDiligence]

MCUR phase-3 trial of CureXcell in venous leg ulcers stopped for futility:

http://finance.yahoo.com/news/macrocure-ltd-provides-futility-analysis-224000889.html

MCUR is also running a phase-3 trial of CureXcell in diabetic foot ulcers, which will report data in4Q15; however, failure of the phase-3 VLU trial probably spells the end of opportunity for MCUR to get CureXcell approved in the US for a broad wound-closure indication—and perhaps for any indication at all. (CureXcell is technically approved in Israel, but it isn’t actively marketed there.)